US5086072A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
Assignee: United States Department of Health and Human Services
•
Filing: 1990-06-18
•
Granted: 1992-02-04
•
Expires: 2010-06-18
Abstract
Abstract A method is disclosed for the treatment of mood disorders, including major depression, by administering an effective mood disorder treating amount of a compound possessing functional antagonist properties for the N-methyl-D-aspartate receptor complex.
Inventors
- 👤 Ramon Trullas
- 👤 Phil Skolnick
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 11:58
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/66; A61K31/13; A61K31/135; A61K31/185; A61K31/19; A61K31/195; A61K31/21; A61K31/215; A61K31/675; A61P; A61P25/00; A61P25/24; A61P25/26
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
49 words
A method for treating mood disorders selected from the group consisting of major depression, bipolar disorder, dysthemia, and seasonal effective disorder in a patient, which comprises: administering to a patient in need thereof, an effective amount of a compound possessing functional antagonist properties for the N-Methyl-D-Aspartate (NMDA) receptor complex.
Claim 2
Independent Claim
49 words
A method for treating mood disorders selected from the group consisting of major depression, bipolar disorder, dysthemia, and seasonal effective disorder in a patient, which comprises: administering to a patient in need thereof, an effective amount of a compound possessing functional antagonist properties for the N-Methyl-D-Aspartate (NMDA) receptor complex.
Claim 3
Dependent Claim
12 words
The method of claim 1, wherein said mood disorder is major depression.
Claim 4
Dependent Claim
26 words
The method of claim 1, wherein the compound which is administered possesses partial agonist properties for the strychnine-insensitive glycine modulatory site of the NMDA receptor complex.
Claim 5
Dependent Claim
89 words
The method of claim 1, wherein the compound which is administered possesses partial agonist properties for the strychnine-insensitive glycine modulatory site of the NMDA receptor complex, and is a compound having the formula: ##STR3## wherein A is --NH 2 , --NHR 1 or --NR 1 R 2 ; B is --OH or --OR 3 ; R 1 , R 2 and R 3 , same or different, are lower alkyl, or lower alkyl substituted by halogen, hydroxyl, alkoxy, oxo, mercapto, aryl or amino; or a pharmaceutically acceptable salt thereof.
Claim 6
Dependent Claim
78 words
The method of claim 1, wherein the compound which is administered possesses partial agonist properties for the strychnine-insensitive glycine modulatory site of the NMDA receptor complex, and is a compound having the formula: ##STR4## wherein A 1 is --NH 2 , --NHR 1 or --NR 1 R 2 ; B 1 is --OH or --OR 3 ; R 1 , R 2 and R 3 , same or different are lower alkyl, or a pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim
25 words
The method of claim 4, wherein the compound is: 1-aminocyclopropanecarboxylic acid, 1-aminocyclopropanecarboxylic acid methyl ester, 1-aminocyclopropanecarboxylic acid ethyl ester, or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
25 words
The method of claim 5, wherein the compound is: 1-aminocyclopropanecarboxylic acid, 1-aminocyclopropanecarboxylic acid methyl ester, 1-aminocyclopropanecarboxylic acid ethyl ester or the pharmaceutically acceptable salts thereof.
Claim 9
Independent Claim
79 words
A method for treating major depression in a patient, comprising: administering to a patient in need thereof an effective amount of a functional antagonist of the N-methyl-D-aspartate (NMDA) receptor complex: administering to a patient in need thereof an effective amount of a functional antagonist of the N-methyl-D-aspartate (NMDA) receptor complex; the functional antagonist which is administered being selected from the group consisting of: 1-aminocyclopropylcarboxylic acid; 1-aminocyclopropylcarboxylic acid methyl ester; 1-aminocyclopropylcarboxylic acid ethyl ester; and the pharmaceutically acceptable salts thereof.
Claim 10
Independent Claim
79 words
A method for treating major depression in a patient, comprising: administering to a patient in need thereof an effective amount of a functional antagonist of the N-methyl-D-aspartate (NMDA) receptor complex: administering to a patient in need thereof an effective amount of a functional antagonist of the N-methyl-D-aspartate (NMDA) receptor complex; the functional antagonist which is administered being selected from the group consisting of: 1-aminocyclopropylcarboxylic acid; 1-aminocyclopropylcarboxylic acid methyl ester; 1-aminocyclopropylcarboxylic acid ethyl ester; and the pharmaceutically acceptable salts thereof.
Claim 11
Dependent Claim
21 words
The method of claim 8, wherein the functional antagonist which is administered is 1-aminocyclopropanecarboxylic acid; or a pharmaceutically acceptable salt thereof.
Claim 12
Dependent Claim
17 words
The method of claim 8, wherein the functional antagonist which is administered is 1-aminocyclopropanecarboxylic acid methyl ester.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-02-03 | 1995-08-05 | 1996-02-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-02-03 | 1999-08-05 | 2000-02-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-02-03 | 2003-08-05 | 2004-02-04 | $7700.00 | Window Closed / Lapsed |